Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) had its target price lowered by Mizuho from $24.00 to $19.00 in a report issued on Monday morning. Mizuho currently has a buy rating on the stock.

A number of other analysts have also commented on the stock. BTIG Research restated a buy rating and set a $18.00 price target (up previously from $15.00) on shares of Ironwood Pharmaceuticals in a research note on Friday, September 23rd. Zacks Investment Research upgraded shares of Ironwood Pharmaceuticals from a hold rating to a buy rating and set a $16.00 price target for the company in a research note on Monday, July 25th. Barclays PLC boosted their price target on shares of Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the company an equal weight rating in a research note on Friday, August 5th. WallachBeth Capital boosted their price target on shares of Ironwood Pharmaceuticals from $15.00 to $17.00 and gave the company a hold rating in a research note on Tuesday, September 27th. Finally, Leerink Swann restated a market perform rating and set a $14.00 price target (up previously from $10.00) on shares of Ironwood Pharmaceuticals in a research note on Monday, August 8th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $15.18.

Shares of Ironwood Pharmaceuticals (NASDAQ:IRWD) traded down 0.88% during mid-day trading on Monday, reaching $15.71. 73,028 shares of the company’s stock were exchanged. The company’s market cap is $2.28 billion. Ironwood Pharmaceuticals has a 52-week low of $7.35 and a 52-week high of $16.17. The company’s 50-day moving average price is $14.69 and its 200 day moving average price is $12.88.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by $0.01. The company earned $54.40 million during the quarter, compared to the consensus estimate of $54.49 million. Ironwood Pharmaceuticals had a negative net margin of 45.21% and a negative return on equity of 94.75%. The business’s revenue was up 96.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.34) EPS. On average, equities research analysts predict that Ironwood Pharmaceuticals will post ($0.75) EPS for the current year.

In related news, Director Lawrence S. Olanoff sold 3,200 shares of the company’s stock in a transaction that occurred on Tuesday, September 6th. The shares were sold at an average price of $13.72, for a total value of $43,904.00. Following the transaction, the director now directly owns 29,305 shares in the company, valued at $402,064.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.17% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sector Gamma AS boosted its position in Ironwood Pharmaceuticals by 25.9% in the first quarter. Sector Gamma AS now owns 2,486,757 shares of the company’s stock valued at $27,205,000 after buying an additional 512,336 shares during the period. Bridger Management LLC acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter worth approximately $56,654,000. A.R.T. Advisors LLC boosted its position in shares of Ironwood Pharmaceuticals by 139.8% in the first quarter. A.R.T. Advisors LLC now owns 198,615 shares of the company’s stock worth $2,172,000 after buying an additional 115,800 shares during the last quarter. Adage Capital Partners GP L.L.C. acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter worth approximately $9,846,000. Finally, Consonance Capital Management LP acquired a new position in shares of Ironwood Pharmaceuticals during the first quarter worth approximately $54,089,000. Institutional investors own 93.96% of the company’s stock.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company’s products Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders.

5 Day Chart for NASDAQ:IRWD

Receive News & Stock Ratings for Ironwood Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.